在转移性结直肠癌中预测化疗反应的AI驱动病理学:一种转移学习方法,使用基于注意力的多实例学习方法
概括
这项研究引入了一种人工智能驱动的病理学方法,用于预测转移性结直肠癌 (mCRC) 中的化疗反应. 该方法提高了预测准确性和可解释性,为个性化瘤学提供了洞察力.
科学领域:
- 在瘤学瘤学.
- 数字病理学数字病理学
- 人工智能的人工智能
背景情况:
- 由于缺乏可靠的生物标志物,难以预测转移性结直肠癌 (mCRC) 中的化疗反应.
- 目前的方法缺乏有效的个性化治疗策略所需的精度.
研究的目的:
- 开发和验证一种人工智能驱动的病理学方法,用于预测mCRC中的化疗反应.
- 用视觉解释来提高预测模型的解释性.
主要方法:
- 在整个幻灯片图像 (WSIs) 上利用转移学习和基于注意力的多实例学习 (MIL).
- 在癌症基因组图谱 (TCGA) 上预先训练了一种深度学习算法,并在多中心mCRC队列上微调它.
- 集成的多中心数据,以提高模型稳定性和减少变化.
主要成果:
- 在预测准确度方面取得了显著的改进,曲线下的面积 (AUC) 从0.54增加到0.68.
- 注意力加权的可视化突出显示了与化疗耐药性相关的瘤微环境特征.
- 与基线模型相比,模型稳定性得到改善,变化性减少.
结论:
- 由转移学习增强的AI驱动的数字病理学,显示了改善mCRC中的化疗反应预测的可行性.
- 该方法为临床决策和生物研究提供了宝贵的见解.
- 该框架支持整合多学科数据,以实现人工智能驱动的个性化瘤学.
更多相关视频
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
472
07:15Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
Published on: August 16, 2020
7.3K
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
